Cost-Effectiveness and Cost-Utility of Intralesional Recombinant Human Epidermal Growth Factor for Adjuvant Treatment of Wagner’s 3 and 4 Diabetic Foot Ulcers
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1880
https://www.valueinhealthjournal.com/article/S1098-3015(16)33246-6/fulltext
Title :
Cost-Effectiveness and Cost-Utility of Intralesional Recombinant Human Epidermal Growth Factor for Adjuvant Treatment of Wagner’s 3 and 4 Diabetic Foot Ulcers
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33246-6&doi=10.1016/j.jval.2016.09.1880
First page :
A673
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1774